Navigation Links
Medivation Announces Participation in Upcoming Conferences
Date:9/9/2009

SAN FRANCISCO, Sept. 9 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following conferences:

  • The BioCentury NewsMakers in the Biotech Industry Conference on Wednesday, September 16, at 11:30 a.m. Eastern Time at the Millennium Broadway Hotel in New York
  • The UBS Global Life Sciences Conference on Wednesday, September 23, at 9:00 a.m. Eastern Time at the Grand Hyatt in New York

Dr. Hung will provide an overview of Medivation and its clinical development programs including dimebon (latrepirdine) for Alzheimer's and Huntington diseases and MDV3100 for prostate cancer.

A live audio webcast of each presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases. With Pfizer, the Company is conducting a broad dimebon clinical development program that i
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 CONNECTION Trial of Dimebon in Patients With Alzheimers Disease
2. Medivation Announces Pricing of Public Offering
3. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
4. Medivation Announces Upcoming Scientific Presentations at Medical Conferences
5. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
6. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
7. Medivation Presents New Data on Dimebons Novel Mechanism of Action
8. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
9. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
10. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
11. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... Company,s Chief Financial Officer has resigned.  The Company has ... Officer who retired in December 2014, as full time ... permanent successor.     Andy Ashworth began ... ensure a smooth transition.  Andy was the Company,s CFO ...
(Date:7/29/2015)... July 29, 2015 ... the addition of the "Global Biosimilars Market, ... The Global Biosimilars Market, 2015 - ... rapidly growing biosimilars market. With the blockbuster biologics ... minimize costs, biosimilars are being viewed as viable ...
(Date:7/29/2015)... SAN DIEGO , July 29, 2015  Pfenex ... quarter 2015 financial results will be released on Thursday, ... 8:30 am Eastern Time, Pfenex management will host a ... a business update.  A press release outlining the financial ... to the call. Please call 1-866-376-8058 (US) ...
(Date:7/29/2015)... QUEBEC CITY , July 29, 2015 /PRNewswire/ ... (the "Company") today announced it has selected an optimized ... important milestone in the development of a new ... The MAPK pathway represents a prime target for ... significant antitumor activities and survival benefits for B-Raf ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... 2011 Auxilium Pharmaceuticals, Inc. (Nasdaq: ... financial results for the fourth quarter and the ... highlighted important commercial, regulatory and clinical development progress ... operational guidance for 2011. (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO) ...
... February 9, 2011 Engineers and scientists collaborating at ... demonstrated the world,s first programmable nanoprocessor. The groundbreaking ... in the journal Nature , represents a significant ... can be assembled from synthesized nanometer-scale components. It ...
... The New England Journal of Medicine (NEJM) ... plus best supportive care (BSC) more than doubled progression-free ... plus BSC in patients with advanced pancreatic neuroendocrine tumors ... (RAD001 In Advanced Neuroendocrine Tumors), were first presented last ...
Cached Biology Technology:Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 2Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 3Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 4Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 5Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 6Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 7Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 8Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 9Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 10Researchers at Harvard and MITRE produce world's first programmable nanoprocessor 2Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 2Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 3Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 4Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 5Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 6Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 7Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 8Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 9Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 10Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 11Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 12
(Date:7/13/2015)... SAN JOSE, Calif. , July 13, 2015 ... the leading developer of human interface solutions, today ... second generation touch and display driver integration (TDDI) ... solution is the first to combine Synaptics , ... expertise with proven display driver technology developed in ...
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, ... ), the leading developer of human interface ... authentication technology, the industry,s first fully hardware ... innovative Match-in-Sensor secure authentication technology is literally ... pattern storage and biometric matching within the ...
(Date:7/7/2015)... June 30, 2015 ... the addition of the "Capacitive Fingerprint Sensors ... To this date, fingerprint sensing technology is ... fingerprint sensors are well developed. This patent landscape ... The domain of capacitive fingerprint sensors ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... focus on forestsas opposed to the entire landscapecould ... poor in developing countries, said a Nairobi-based agroforestry ... forest degradation is driven by forces outside forests, ... land uses that involve the whole landscape, not ...
... This release is available in French . ... Laval, in collaboration with Nova Scotia Agricultural College, have discovered ... to double the lifespan of Christmas trees in homes. The ... scientific journal Trees . The researchers have identified ...
... Personality is not just a feature unique to humans ... have revealed that also brown trout have individual characters ... the Department of Zoology at the University of Gothenburg ... trout from watercourses on the west coast of Sweden. ...
Cached Biology News:Towards an efficient, effective and equitable REDD+ 2Towards an efficient, effective and equitable REDD+ 3Towards an efficient, effective and equitable REDD+ 4Researchers discover a way to delay Christmas tree needle loss 2